(Q37896031)

25 August 2017

1 reference

title

Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology (English)

1 reference

25 August 2017

main subject

cervix uterine cancer

1 reference

2

Rosemary H Tambouret

1 reference

25 August 2017

Ha Thanh Nishino

1

1 reference

25 August 2017

David C Wilbur

series ordinal

3

1 reference

25 August 2017

publication date

29 June 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

119

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

219-227

1 reference

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Immune responses to human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

The natural history of cervical HPV infection: unresolved issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance Papanicolaou results in SurePath and ThinPrep specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Human papillomavirus type 16 and 18 gene expression in cervical neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

p16(INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. I: Experience with squamous lesions in 189 consecutive cervical biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

P16INK4a as an adjunct marker in liquid-based cervical cytology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Using biomarkers as objective standards in the diagnosis of cervical biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Gain of the human telomerase RNA gene TERC at 3q26 is strongly associated with cervical intraepithelial neoplasia and carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

New epidemiology of human papillomavirus infection and cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

Commentary on: Statement on HPV DNA test utilization

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

ACOG Practice Bulletin no. 109: Cervical cytology screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

Cytological distinction between high-risk and low-risk human papillomavirus infections in SurePath liquid-based cell preparations

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

A comparison of two methods to determine the presence of high-risk HPV cervical infections

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.20161

7 January 2021

Identifiers

DOI

10.1002/CNCY.20161

1 reference

25 August 2017

1 reference